

**REMARKS**

The Office Action has been carefully studied. The examiner considers the application to contain ten inventions or groups of inventions (Groups 1-10) which are not so linked as to form a single general inventive concept under PCT Rule 13.1 and requires election of a single invention to which the claims must be restricted.

Applicants elect Group 9, presently comprising claims 5, 9 and 11, with traverse. Insofar as Groups 7-9 are concerned, traversal is based on the special technical feature of administering a leptin or a homologue or derivative thereof. The inhibitor of angiogenesis, which includes VEGF inhibitors regardless of whether the production or action of VEGF is inhibited, is optional. Accordingly, Groups 7-9 share the same special technical feature. Moreover, as presently amended, the inhibitors of angiogenesis recited in claim 9 encompass VEGF inhibitors (support is found in the specification at page 9, lines 19-23). Withdrawal of the restriction insofar as Groups 7-9 are concerned is therefore respectfully requested.

With regard to the election of species requirement from the species (i)-(xi) of VEGF inhibitors, applicants elect the species of (iv) CSC. It is understood however that upon allowance of a generic claim, i.e., claims 9 and/or 11,

Appln. No. 10/070,295  
Amd. dated December 15, 2005  
Reply to Office Action of November 15, 2005

applicants will be entitled to consideration of claims to  
additional species.

Favorable consideration and allowance are respectfully  
solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By

A handwritten signature in black ink, consisting of a large, stylized 'A' with a horizontal line extending to the right, and a vertical line crossing it.

Allen C. Yun

Registration No. 37,971

ACY:pp  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
G:\BN\I\inl2\Rubinstein7\pto\amd to OA 11-15-05.doc